Infectious Disease Deal Benchmarks 2026

Infectious disease licensing in 2026 spans antivirals, novel antibiotics, and next-generation vaccines. Phase 2 small molecule deals in the infectious disease space carry a median total deal value of $1.9B, with upfront payments between $281M and $750M. HIV long-acting regimens, HBV functional cures, and broad-spectrum antivirals represent the highest-value deal categories.

Deal structures in infectious disease are shaped by the unique dynamics of antimicrobial stewardship, pandemic preparedness funding, and government procurement contracts. Development milestones average $313M, with regulatory milestones of $328M often tied to expedited pathways such as QIDP designation. Commercial milestones of $783M reflect both commercial and public-health market opportunities.

Royalty rates for infectious disease deals range from 7.7% to 15.4% at the base tier. Novel antibiotic deals often carry lower base rates but include pull incentive and subscription model-linked commercial milestones. Antiviral deals, particularly in HIV and HBV, support higher royalty structures given the chronic treatment paradigm and large patient populations.